Biomarkers Predict Chronic Kidney Disease Progression
Novel Biomarkers show promise for Personalized Chronic Kidney Disease Management
Table of Contents
Chronic kidney disease (CKD) affects millions worldwide,and predicting disease progression and mortality risk remains a notable clinical challenge. Recent research published in the journal of the American society of Nephrology suggests that a panel of novel biomarkers may offer comparable predictive power to established risk factors, and importantly, provide insights into the underlying mechanisms driving CKD progression - potentially paving the way for more personalized treatment strategies.
Biomarker Models Demonstrate Strong Predictive Accuracy
The study, conducted as part of the National Unified Renal Translation Research Enterprise – Chronic Kidney Disease (NURTuRE-CKD) trial (NCT04084145), evaluated the performance of biomarker-based risk prediction models against traditional risk factors. Researchers analyzed data to predict kidney failure and all-cause mortality.
The results demonstrate encouraging diagnostic accuracy. The biomarker-based risk factor model achieved a C-index of 0.80 (95% CI 0.76-0.84), indicating strong discrimination in predicting outcomes. Notably,the biomarker model (C-index: 0.78 [95% CI 0.76-0.81]) showed numerically higher discrimination for a composite outcome compared to models relying solely on established risk factors (C-index: 0.77 [95% CI 0.74-0.80]).
Statistical analysis confirmed that adding biomarkers to existing risk factors resulted in a statistically significant, albeit small, improvement in discrimination (C-index: 0.80 [95% CI 0.77-0.82]; P < .01). This suggests that biomarkers don't necessarily replace established methods, but rather enhance their predictive capabilities. "Our research shows that these novel biomarker models offer predictive results comparable to established methods, but the key finding here is that we can use these biomarkers to understand the underlying mechanisms of disease progression, potentially paving the way to more personalised treatments and medicines for CKD patients," explained Dr. Tony Onoja, lead author of the study and research fellow at the University of Surrey, in a news release.
understanding Disease Mechanisms for Personalized Medicine
Beyond predictive accuracy, a key strength of the biomarker approach lies in its potential to elucidate the biological processes driving CKD. By identifying specific biomarkers associated with disease progression and mortality,researchers can gain a more nuanced understanding of individual patient risk profiles. This understanding is crucial for developing targeted therapies and tailoring treatment plans to individual needs.
“Our study demonstrates that specific biomarkers can offer a more nuanced understanding of a patient’s disease progression and mortality risk and the disease’s ongoing activity,” stated Professor Nophar Geifman, senior author and professor of health and biomedical informatics at the University of Surrey. “Further research is needed to evaluate how these biomarkers change in response to current treatments, and their clinical utility in patient care and in personalised medicine.”
Limitations and Future Directions
While the findings are promising, the authors acknowledge several limitations. Currently, data on cardiovascular events and cause of death are unavailable, hindering a complete assessment of long-term outcomes. the generalizability of the findings may also be limited, as the study cohort may not fully represent all CKD populations. Specifically, the results may not be directly applicable to patients with early-stage CKD, those receiving care in primary care settings, or individuals from diverse racial and/or ethnic backgrounds.
A further limitation highlighted by the researchers is the lack of sex-stratified analysis of biomarker values. Given known sex-based differences in biomarker distribution and CKD outcomes,future studies must specifically address this gap to ensure equitable and accurate risk prediction for all patients.Future research will focus on evaluating biomarker responses to existing treatments and assessing their clinical utility in guiding patient care. Further investigation is also needed to validate these findings in larger, more diverse populations and to develop standardized biomarker assays for widespread clinical implementation. The ultimate goal is to integrate these biomarkers into routine clinical practice, enabling clinicians to provide more personalized and effective care for individuals living with CKD.REFERENCES
- Onoja A, McDonnell T, Annessi I, et al. Biomarkers of Kidney Failure and All-Cause Mortality in CKD. J Am Soc Nephrol. Published on 2025, June 20. doi:10.1681/ASN.0000000767
- National Unified Renal Translation research Enterprise - Chronic Kidney Disease (NURTuRE-CKD).ClinicalTrials.gov identifier: NCT04084145.